Abstract: AIM: To compare the clinical therapeutic effects and cost-effectiveness of Insulin Aspart 30 Injection(NovoMix30FlexPen) among different therapeutic regimens for diabetic patients.METHODS: A retrospective study was conducted in which a total of 135 cases with type 2 diabetes mellitus were divided into 3 groups by random(A: NovoMix30FlexPen for morning or night for 6 months; B: NovoMix30FlexPen prior three meals for 6 months; C: NovoMix30FlexPen for morning or night + Acarbose Tablets for 6 months).RESULTS: The effective rates of FBG were 84.4％ in Group A versus 86.7％ in Group B and 91.1％ in Group C (P>0.05), the effective rates of PBG2h were 91.1％, 91.1％ and 88.9％, and the effective rates of HbA1c were 75.6％, 80.0％, 77.8％ respectively.CONCLUSION: Blood sugar level can be controlled to an ideal level through the three treatment schemes; while Group C is better considering the cost-effectiveness ratios, and it has the clinical value of popularization.

Key words: Insulin Aspart 30 Injection, Therapeutic regimen, Type 2 diabetes, Cost-effectiveness analysis